912
Z. Wu et al. / Bioorg. Med. Chem. Lett. 14 (2004) 909–912
Further efforts along this line will be reported in due
course.
10. Yang, J. C.; Haworth, L.; Sherry, R. M.; Hwu, P.;
Schwartzentruber, D. J.; Topalian, S. L.; Steinberg, S. M.;
Chen, H. X.; Rosenberg, S. A. N. Engl. J. Med. 2003, 349,
427.
11. Fraley, M. E.; Hoffman, W. F.; Rubino, R. S.; Hungate,
R. W.; Tebben, A. J.; Rutledge, R. Z.; McFall, R. C.;
Huckle, W. R.; Kendall, R. L.; Coll, K. E.; Thomas, K. A.
Bioorg. Med. Chem. Lett. 2002, 12, 2767.
12. Fraley, M. E.; Rubino, R. S.; Hoffman, W. F.; Ham-
baugh, S. R.; Arrington, K. L.; Hungate, R. W.;
Bilodeau, M. T.; Tebben, A. J.; Rutledge, R. Z.; Kendall,
R. L.; McFall, R. C.; Huckle, W. R.; Coll, K. E.; Thomas,
K. A. Bioorg. Med. Chem. Lett. 2002, 12, 3537.
Acknowledgements
We thank Kenneth D. Anderson for solubility determi-
nation. We also thank Dr. Art Coddington, Dr. Chuck
Ross and Dr. Harri Ramjit for mass spectral analyses.
References and notes
13. Bilodeau, M. T.; Cunningham, A. M.; Koester, T. J.;
Ciecko, P. A.; Coll, K. E.; Huckle, W. R.; Hungate, R. W.;
Kendall, R. L.; McFall, R. C.; Mao, X.; Rutledge, R. Z.;
Thomas, K. A. Bioorg. Med. Chem. Lett. 2003, 13, 2485.
14. All target compounds were fully characterized by 1H
NMR and mass spectroscopy.
1. Adamis, A. P.; Shima, D. T.; Yeo, K. T.; Yeo, T. K.;
Brown, L. F.; Berse, B.; D’Amore, P. A.; Folkman, J.
Biochem. Biophys. Res. Commun. 1993, 193, 631.
2. Giatromanolaki, A.; Sivridis, E.; Athanassou, N.; Zois,
E.; Thorpe, P. E.; Brekken, R. A.; Gatter, K. C.; Harris,
A. L.; Koukourakis, I. M.; Koukourakis, M. I. J. Path.
2001, 194, 101.
15. The KDR IC50 value represents biochemical inhibition of
phosphorylation of a poly-Glu/Tyr (4:1) peptide substrate
by isolated KDR kinase (cloned and expressed as a GST-
fusion protein), see: Kendall, R. L.; Rutledge, R. Z.; Mao,
X.; Tebben, A. L.; Hungate, R. W.; Thomas, K. A. J.
Biol. Chem. 1999, 274, 6453. Values are reported as single
determinations or as the average of at least two determin-
ationsÆstandard deviation.
3. Detmar, M. Dermatol. Sci. 2000, 24, S78.
4. (a) For reviews, see: Carmeliet, P.; Jain, R. K. Nature
2000, 407, 249. (b) Folkman, J. Nature Med. 1995, 1, 27.
5. (a) Veikkola, T.; Karkkainen, M.; Claesson-Welsh, L.;
Alitalo, K. Cancer Res. 2000, 60, 203. (b) Thomas, K. A.
J. Biol. Chem. 1996, 271, 603.
16. Compounds 10f and 10g were prepared similarly accord-
ing to the following Scheme:
6. Lin, Y. S.; Nguyen, C.; Mendoza, J. L. J. Pharm. Exp.
Ther. 1999, 188, 371.
7. Lu, D.; Jimenez, X.; Zhang, H.; Bohlen, P.; Witte, L.;
Zhu, Z. Int. J. Cancer 2002, 97, 393.
8. Holash, J.; Davis, S.; Papadopoulos, N.; Croll, S. D.; Ho,
L.; Russell, M.; Boland, P.; Leidich, R.; Hylton, D.;
Burova, E.; Ioffe, E.; Huang, T.; Radziejewski, C.; Bailey, K.;
Fandl, J. P.; Daly, T.; Wiegand, S. J.; Yancopoulos, G. D.;
Rudge, J. S. Proc. Natl. Acad. Sci. U.S.A. 2002, 99, 11393.
9. (a) For recent reviews, see: Bilodeau, M. T.; Fraley, M. E.;
Hartman, G. D. Expert Opin. Investig. Drugs 2002, 11,
737. (b) Boyer, S. J. Curr. Top. Med. Chem. 2002, 2, 973.
17. Traxler, P.; Furet, P. Pharmacol. Ther. 1999, 82, 195.